Streetbeat News

Products Services

BFLY

Butterfly Network, Inc. (BFLY) has entered into a commercial agreement with Mendaera to integrate Butterfly's Ultrasound-on-Chip technology into Mendaera's next-generation robotic system for interventional procedures. The partnership is expected to generate revenue for Butterfly from each unit sold post-commercialization. The product, which aims to improve precision in image-guided interventions, is anticipated to be submitted to the FDA by 2025. This follows Mendaera's $24 million Series A funding round and the completion of their research and design process.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:07 pm

CLMB

Climb Channel Solutions, a subsidiary of Climb Global Solutions, Inc. (NASDAQ:CLMB), has announced a partnership with DNSFilter to distribute their DNS security solutions in North America. This partnership aims to mitigate cyber-attack risks by providing resellers and MSPs with tools to protect networks and sensitive data. DNSFilter, which serves 26 million users monthly, uses machine learning to identify online threats. Climb Channel Solutions will be the sole distributor, enhancing their North American offerings with emerging and disruptive technologies.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:03 pm

FMST

FMSTW

Foremost Lithium has informed Benzinga that their exploration target includes the B-1 spodumene bearing pegmatite dyke, with plans to extend the mineralization laterally towards the B-2 and B-3 pegmatites. This indicates a strategic move to expand their lithium resource base, which is a key component in electric vehicle batteries and energy storage solutions.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:00 pm

FMST

Foremost Lithium Resource & Technology Ltd. (NASDAQ:FMST) has announced plans for a 15-hole, 2,500-meter diamond drill program at the Jean Lake Lithium/Gold Property in Manitoba, Canada, targeting the B-1 spodumene-bearing pegmatite dyke. The drilling, expected to start in 1Q24, aims to expand exploration and potentially uncover more gold deposits and lithium mineralization. Past drilling revealed gold concentrations and adjacent areas showed high lithium concentrations. FMST has secured $3 million in credit financing for the program, with flexible repayment terms. Shares of FMST rose 10.98% to $3.74 in premarket trading on Tuesday.

Portfolio Pulse from Akanksha Bakshi

December 19, 2023 | 1:00 pm

FMST

FMSTW

Foremost Lithium has announced plans to commence drilling on its Jean Lake Lithium and Gold Property, as exclusively reported by Benzinga. This development could indicate potential growth and value extraction from the property, which may be of interest to investors in the lithium and gold sectors.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:00 pm

HARP

Harpoon Therapeutics has announced that an abstract for HPN328, its treatment for small cell lung cancer and other neuroendocrine tumors, has been accepted for a rapid oral presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:56 pm

TSLA

Elon Musk announced that Tesla will offer a modification package for the Cybertruck, allowing it to wade on water for at least 100 meters. The mod involves upgrading cabin door seals and is in line with Musk's vision of the Cybertruck being able to serve as a boat. The vehicle also features a 'wade' mode for navigating water.

Portfolio Pulse from Anan Ashraf

December 19, 2023 | 12:47 pm

SUPN

Supernus Pharmaceuticals has entered into an agreement with Knight Therapeutic, granting Knight the rights to seek regulatory approval and commercialize Qelbree in Canada for the treatment of ADHD. The financial terms of the agreement have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:40 pm

BIIB

TEVA

The European Commission has withdrawn marketing authorizations for generic versions of Biogen's multiple sclerosis drug Tecfidera, which is protected until February 3, 2025. This affects generics by Accord, Mylan, Neuraxpharm, Polpharma, and Teva. Biogen has taken legal steps to enforce its market exclusivity and confirms it can supply the entire European market with Tecfidera.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:38 pm

AVXL

Anavex Life Sciences Corp. (NASDAQ:AVXL) has received agreement from the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) to submit a Marketing Authorization Application in the EU for oral blarcamesine, a treatment for Alzheimer's disease. This step is crucial for Anavex as it moves closer to potentially marketing its drug in the European Union.

Portfolio Pulse from Charles Gross

December 19, 2023 | 12:36 pm